Your session is about to expire
← Back to Search
Behavioural Intervention
Active for Traumatic Brain Injury
N/A
Waitlist Available
Research Sponsored by Neurohabilitation Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Summary
- Brief Summary: Prospective, cohort, open-label study. The cohort consists of people who have a chronic balance dysfunction due to a mild to moderate traumatic brain injury (TBI). All participants will participate in a 14-week PoNS Treatment protocol - a combination of symptom specific physical exercises and repeated use of the PoNS device. Subjects who meet the initial screening entrance criteria will be scheduled for a baseline assessment to evaluate balance and gait. Subjects will then begin the PoNS Treatment program and re-perform some assessments at 2, 5 and 14 weeks evaluating their functional improvements.
Eligible Conditions
- Traumatic Brain Injury
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: ActiveExperimental Treatment1 Intervention
PoNS Treatment will consist of three stages: an in-clinic training program, a home training program, and an extended home training program. During all stages of the study, subjects will complete three training sessions per day, morning, afternoon and evening, 6 days per week.
Find a Location
Who is running the clinical trial?
Neurohabilitation CorporationLead Sponsor
6 Previous Clinical Trials
216 Total Patients Enrolled
Helius Medical IncLead Sponsor
9 Previous Clinical Trials
356 Total Patients Enrolled
Ohio State UniversityOTHER
866 Previous Clinical Trials
655,137 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger